Racial differences between blacks and whites with systemic sclerosis

Current Opinion in Rheumatology

Volumn 24, Issue 6, 2012, Pages 642-648

  Silver, Richard M ^a   Bogatkevich, Galina ^a   Tourkina, Elena ^a   Nietert, Paul J ^a   Hoffman, Stanley ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

caveolin 1; health disparities; HGF; systemic sclerosis; TGF

Indexed keywords

CAVEOLIN 1; COLLAGEN; DNA TOPOISOMERASE; INTERLEUKIN 6; OSTEOPROTEGERIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RENIN; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SMAD2 PROTEIN; SMAD3 PROTEIN; SOMATOMEDIN BINDING PROTEIN 3; STEM CELL FACTOR; TENASCIN; THROMBOPOIETIN; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

DIASTOLIC BLOOD PRESSURE; DISEASE PREDISPOSITION; DISEASE SEVERITY; GENETIC PREDISPOSITION; GENETIC TRANSCRIPTION; HUMAN; METABOLIC SYNDROME X; MICROALBUMINURIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RACE DIFFERENCE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC SCLEROSIS; SYSTOLIC BLOOD PRESSURE;

AFRICAN AMERICANS; CAVEOLIN 1; DISEASE SUSCEPTIBILITY; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION TO DISEASE; HEALTH STATUS DISPARITIES; HEPATOCYTE GROWTH FACTOR; HUMANS; PPAR GAMMA; SCLERODERMA, SYSTEMIC; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84867032498     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e328356d9dc     Document Type: Review

References (59)

1. Mayes MD, Lacey JV Jr, Beebe-Dimmer J, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003; 48:2246-2255. (Pubitemid 36959206)
2. Laing TJ, Gillespie BW, Toth MB, et al. Racial differences in scleroderma among women in Michigan. Arthritis Rheum 1997; 40:734-742. (Pubitemid 27157581)
3. Krishnan E, Furst DE. Systemic sclerosis mortality in the United States: 1979-1998. Eur J Epidemiol 2005; 20:855-861. (Pubitemid 41622182)
4. McNearney TA, Reveille JD, Fischbach M, et al. Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors. Arthritis Rheum 2007; 57:318-326. (Pubitemid 47164096)
5. Nietert PJ, Mitchell HC, Bolster MB, et al. Racial variation in clinical and immunological manifestations of systemic sclerosis. J Rheumatol 2006; 33:263-268. (Pubitemid 43209301)
6. Greidinger EL, Flaherty KT, White B, et al. African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease. Chest 1998; 114:801-807. (Pubitemid 28433744)
7. Mendoza F, Derk CT. Systemic sclerosis mortality in the United States 1999-2002: implications for patient care. J Clin Rheumatol 2007; 13:187-192. (Pubitemid 47356785)
8. Nashid M, Khanna PP, Furst DE, et al. Gender and ethnicity differences in patients with diffuse systemic sclerosis: analysis from three large randomized clinical trials. Rheumatology 2011; 50:335-342.
9. Nietert PJ, Silver RM, Mitchell HC, et al. Demographic and clinical factors associated with in-hospital death among patients with systemic sclerosis. J Rheumatol 2005; 32:1888-1892. (Pubitemid 41429017)
10. Beall AD, Nietert PJ, Taylor MH, et al. Ethnic disparities among patients with pulmonary hypertension associated with systemic sclerosis. J Rheumatol 2007; 34:1277-1282. (Pubitemid 46898109)
11. Reveille JD, Fischbach M, McNearney T, et al. Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunologic determinants. Semin Arthritis Rheum 2001; 30:332-346. (Pubitemid 32298859)
12. Nietert PJ, Silver RM. Patterns of hospital admissions and emergency room visits among patients with scleroderma in South Carolina, USA. J Rheumatol 2003; 30:1238-1243. (Pubitemid 36666347)
13. Steen VD, Powell DT, Medsger TA Jr. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988; 32:196-203. (Pubitemid 18088039)
14. Reveille JD, Durban E, Goldstein R, et al. Racial differences in the frequencies of scleroderma related autoantibodies. Arthritis Rheum 1992; 35:216-218.
15. Kuwana M, Kaburaki J, Arnett FC, et al. Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA topoisomerase I antibody. Arthritis Rheum 1999; 42:465-474. (Pubitemid 29136094)
16. Steen VD, Ziegler GL, Rodnan GP, Medsger TA Jr. Clinical an laboratory associations of anticentromere antibody in patients with progressive systemic sclerosis. Arthritis Rheum 1984; 27:125-131. (Pubitemid 14191016)
17. Steen VD, Domsic RT, Lucas M, et al. A clinical and serologic comparison of African-American and Caucasian patients with systemic sclerosis. Arthritis Rheum 2012; May 10. doi 10.1002/art.34482. [Epub ahead of print]
18. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000; 342:1350-1358. (Pubitemid 30408720)
19. Wei J, Bhattacharyya S, Tourtellotte WG, Varga J. Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy. Autoimmun Rev 2011; 267-275.
20. Kawakami T, Ihn H, Xu W, et al. Increased expression of TGF-beta receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-beta signaling to scleroderma phenotype. J Invest Dermatol 1998; 110:47-51. (Pubitemid 28086062)
21. Eiser AR. Does over-expression of transforming growth factor-beta account for the increased morbidity in African-Americans?: possible clinical study and therapeutic implications. Med Hypotheses 2010; 75:418-421.
22. Zhao Y, Wen Y, Polan ML, et al. Increased expression of latent TGF-beta binding protein-1 and fibrillin-1 in human uterine leiomyomata. Mol Hum Reprod 2007; 13:343-349. (Pubitemid 47061645)
23. Beanes SR, Dang C, Soo C, Ting K. Skin repair and scar formation: the central role of TGF-beta. Expert Rev Mol Med 2003; 5:1-22.
24. Jonth AC, Silveira L, Fingerlin TE, et al. TGF-beta 1 variants in chronic beryllium disease and sarcoidosis. J Immunol 2007; 179:4255-4262.
25. Tripathi RC, Li J, Chan WF, Tripathi BJ. Aqueous humor in glaucomatous eyes contains an increased level of TGF-beta 2. Exp Eye Res 1994; 59:723-727.
26. Klag MJ, Whelton PK, Randall BL, et al. End-stage renal disease in African-American and white men. 16-year MRFIT findings. JAMA 1997; 277:1293-1298. (Pubitemid 27194353)
27. Suthanthiran M, Baogui L, Song JO, et al. Transforming growth factor beta1 hyper-expression in African-American hypertension: a novel mediator of hypertension and/or target organ damage. Proc Natl Acad Sci USA 2000; 97:3479-3484. (Pubitemid 30183328)
28. Suthanthiran M, Gerber LM, Schwartz JE, et al. Circulating transforming growth factor beta1 levels and the risk for kidney disease in African Americans. Kidney Int 2009; 76:72-80.
29. Gurram M, Pahwa S, Frieri M. Augmented interleukin-6 secretion in collagenstimulated peripheral blood mononuclear cells from patients with systemic sclerosis. Ann Allergy 1994; 73:493-496.
30. Feghali CA, Bost KL, Boulware DW, Levy LS. Mechanisms of pathogenesis of scleroderma. I. Overproduction of interleukin 6 by fibroblasts cultured from affected skin sites of patients with scleroderma. J Rheumatol 1992; 19:1207-1211.
31. Hasegawa M, Sato S, Fujimoto M, et al. Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis. J Rheumatol 1998; 25:308-313. (Pubitemid 28088260)
32. Sato S, Hasegawa M, Takehara K. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci 2001; 27:140-146. (Pubitemid 32781022)
33. Shima Y, Kuwahara Y, Murota H, et al. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology 2010; 49:2408-2412.
34. Hutchings A, Guay-Woodford L, Thomas JM, et al. Association of cytokine single nucleotide polymorphisms with B7 costimulatory molecules in kidney allograft recipients. Pediatr Transplant 2002; 6:69-77. (Pubitemid 34269739)
35. Bogatkevich GS, Ludwicka-Bradley A, Highland KB, et al. Impairment of the antifibrotic effect of hepatocyte growth factor in lung fibroblasts from African Americans: possible role in systemic sclerosis. Arthritis Rheum 2007; 56:2432-2442. (Pubitemid 47173591)
36. Brossett, Veraldi KL, Pilewski JM, et al. Localized expression of tenascin in systemic sclerosis-associated pulmonary fibrosis and its regulation by insulinlike growth factor binding protein 3. Arthritis Rheum 2012; 64:272-280.
37. Beretta L, Cappiello F, Moore JH, et al. Ability of epistatic interactions of cytokine single-nucleotide polymorphisms to predict susceptibility to disease subsets in systemic sclerosis patients. Arthritis Rheum 2008; 59:974-983. (Pubitemid 351990994)
38. Tourkina E, Richard M, Gooz P, et al. Antifibrotic properties of caveolin-1 scaffolding domain in vitro and in vivo. Am J Physiol Lung Cell Mol Physiol 2008; 294:L843-L861.
39. Tourkina E, Gooz P, Pannu J, et al. Opposing effects of protein kinase Calpha and protein kinase Cepsilon on collagen expression by human lung fibroblasts are mediated via MEK/ERK and caveolin-1 signaling. J Biol Chem 2005; 280:13879-13887. (Pubitemid 40517287)
40. Del Galdo F, Sotgia F, de Almeida CJ, et al. Decreased expression of caveolin 1 in patients with systemic sclerosis: crucial role in the pathogenesis of tissue fibrosis. Arthritis Rheum 2008; 58:2854-2865.
41. Couet J, Li S, Okamoto T, et al. Identification of peptide and protein ligands for the caveolin-scaffolding domain. Implications for the interaction of caveolin with caveolae-associated proteins. J Biol Chem 1997; 272:6525-6533. (Pubitemid 27118133)
42. Oka N, Yamamoto M, Schwencke C, et al. Caveolin interaction with protein kinase C. Isoenzyme-dependent regulation of kinase activity by the caveolin scaffolding domain peptide. J Biol Chem 1997; 272:33416-33421. (Pubitemid 28023695)
43. Rybin VO, Xu X, Steinberg SF. Activated protein kinase C isoforms target to cardiomyocyte caveolae: stimulation of local protein phosphorylation. Circ Res 1999; 84:980-988. (Pubitemid 29227677)
44. Wang XM, Zhang Y, Kim HP, et al. Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis. J Exp Med 2006; 203:2895-2906. (Pubitemid 46026167)
45. Razani B, Zhang XL, Bitzer M, et al. Caveolin-1 regulates transforming growth factor (TGF)-beta/SMAD signaling through an interaction with the TGF-beta type I receptor. J Biol Chem 2001; 276:6727-6738.
46. Le Saux J, Teeters K, Miyasato SK, et al. Down-regulation of caveolin-1, an inhibitor of transforming growth factor-beta signaling, in acute allergeninduced airway remodeling. J Biol Chem 2008; 283:5760-5768.
47. Yan SR, Fumagalli L, Berton G. Activation of SRC family kinases in human neutrophils. Evidence that p58C-FGR and p53/56LYN redistributed to a Triton X-100-insoluble cytoskeletal fraction, also enriched in the caveolar protein caveolin, display an enhanced kinase activity. FEBS Lett 1996; 380:198-203.
48. Uhal BD. Apoptosis in lung fibrosis and repair. Chest 2002; 122:293S-298S. (Pubitemid 36043016)
49. Trojanowska M. Noncanonical transforming growth factor beta signaling in scleroderma fibrosis. Curr Opin Rheumatol 2009; 21:623-629.
50. Di Guglielmo GM, Le Roy C, Goodfellow AF, Wrana JL. Distinct endocytic pathways regulate TGF-beta receptor signalling and turnover. Nat Cell Biol 2003; 5:410-421. (Pubitemid 36592263)
51. Del Galdo F, Lisanti MP, Jimenez SA. Caveolin-1, transforming growth factor-beta receptor internalization, and the pathogenesis of systemic sclerosis. Curr Opin Rheumatol 2008; 20:713-719.
52. Tourkina E, Richard M, Oates J, et al. Caveolin-1 regulates leucocyte behaviour in fibrotic lung disease. Ann Rheum Dis 2010; 69:1220-1226.
53. Tourkina E, Bonner M, Oates JC, et al. Altered monocyte and fibrocyte phenotype and function in scleroderma interstitial lung disease: reversal by caveolin-1 scaffolding domain peptide. Fibrogenesis Tissue Repair 2011; 4:15.
54. Mizuno S, Matssumoto K, Li MY, Nakamura T. HGF reduces advancing lung fibrosis in mice: a potential role for MMP-dependent myofibroblast apoptosis. FASEB J 2005; 19:580-582. (Pubitemid 40471250)
55. Hishino K, Satoh T, Kawaguchi Y, Kuwana M. Association of hepatocyte growth factor polymorphism with severity of interstitial lung disease in Japanese patients with systemic sclerosis. Arthritis Rheum 2011; 63: 2465-2472.
56. Bogatkevich GS, Ludwicka-Bradley A, Highland KB, et al. Down-regulation of collagen and connective tissue growth factor expression with hepatocyte growth factor in lung fibroblasts from white scleroderma patients via two signaling pathways. Arthritis Rheum 2007; 56:3468-3477. (Pubitemid 47585443)
57. Wei J, Ghosh AK, Sargent JL, et al. PPARg downregulation by TGFb in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis. PLoS One 2010; 5:e13778.
58. Bogatkevich GS, Highland KB, Akter T, Silver RM. The PPARg agonist rosiglitazone is antifibrotic for scleroderma lung fibroblasts: mechanisms of action and differential racial effects. Pulm Med 2012; Article ID 545172, 1-9.
59. Li Y, Wen X, Spataro BC, et al. Hepatocyte growth factor is a downstream effector that mediates the antifibrotic actions of peroxisome proliferatoractivated receptor-g agonists. J Am Soc Nephrol 2006; 17:54-56.